Thank you very much. Good morning or good day, everybody on the call. It's a pleasure, as CEO for CellaVision, to have the opportunity to present our Q1 interim report today. It'll be a two section presentation, so we'll first have a company presentation where I will elaborate on who we are, what we do, and how and where we play. This is the basis for the Q1 results that I'm happy to present. Then Magnus and Michael will be happy to have the discussion in the Q&A session. Next slide, please. I honestly think you can probably press twice. The first slide, which will come up, is about creating value in healthcare. We are in the field of hematology, and our vision is really to become, and we are, the leader of global digitalization and automation of blood analysis, both in the human segment but also in the vet segment. We have a world-leading position within digital cell morphology, which has been introduced and acquired over the past two decades. In short, our vision is to replace microscopes in laboratories. However, it goes beyond just traditional microscopes. It is really about offering a complete lab workflow and providing diagnostic certainty. On the photo, you can actually see what we do. Our solution delivers images of stained blood, so we can take high-resolution images of blood cells. We have algorithms and artificial intelligence that will manage the interpretation, so we can do cell classification and characterization. That is what we do. If we take the next slide, we get into the area of where we play. Currently, we have a considerable penetration in the large labs. The large hematology labs are defined by labs that are doing more than 130 samples per day. That's how we view the market. We collaborate, and we are very adjacent in the workflow to our distribution partners that I'll talk a bit about later. These are the companies that are doing the blood sampling. They're processing their samples through complete blood counters. The process is, or I should say, the market is 2.5 billion blood samples per year. That's the size of it. These samples are processed in the cell counters, and then approximately 15% of those would display abnormalities in the cell counter. These are blood samples that could be candidates for anemia, infections, or certain cancers like leukemia, myeloma. These are then subject for microscopic analysis. This is where we come into play. We provide the stains, we provide the digital cell morphology analysis. What you see on the right-hand side of this slide is that we've penetrated about 22% of this market. We're on an upward trajectory, and we're up against competition, being the conventional, traditional microscope, which is short of 80% today. There's still a considerable share and market to tap into. Next slide, please. The same value proposition is also applicable for the medium to the smaller labs. This is not a segment that we've been able to address considerably with our solutions, but we are actually now. That you will learn. We have in this segment about 100,000 labs, one-third of them being medium, and then a large pool of small labs doing less than 30 samples per day. We consider this market to be somewhat smaller than the large lab market, 1.5 billion blood samples. Again, working closely, interacting in the workflow with the companies having the cell counters. However, in this segment, there is a change because we, as you will see on one of the next couple of slides, we are actually also offering in this part a slide smearing and a staining system for the low-volume segment. Here we are substituting our stains from RAL, branded RAL Diagnostics. We're actually taking a larger share of the value chain here. This is a segment which has not been penetrated. We launched the DC-1. We launched in Europe in 2019. We got approval for the product in Q4, last quarter, Q4 2020, in the U.S. We're on our way, and we are in registration process in China. We have not penetrated the market. However, we are seeing adoption, and I'll get back to that a bit later. Next slide, please. On the next slide, we talk about our partnering and our business model. We are commercializing our solutions in an indirect business model. It's based on partnerships with the large hematology players and the distributors in the field, and we have agreements with all the different players. In combination with working with our distribution partners, we also have our own market support organization who supports both our partners in conveying the value proposition of digital cell morphology, but they're also working with the end user to make sure we really demonstrate the potential of what we offer to the market. Manufacturing wise, we've also chosen, in fact, a combination, but it's a partnering model where we have outsourced our manufacturing in Sweden with regards to instruments, while due to the, or as part of the acquisition with RAL, we actually have our own reagent manufacturing in Bordeaux, in the southern part of France. Totally, we have 180 people in our organization. Just over 100 here in Sweden, 50 in France, and the remaining part supporting our partners in the countries. That is a presence of 18 markets. In fact, we support 40 markets. We have physical presence in 18 different markets. Which leads me onto the next slide, please, where it kind of displays our strategic agenda. Below our strategic agenda topics or themes, we have strategic initiatives, and we have strategic actions. Here we will just show the high-level display and number 1 and number 2 talks about geographic expansion in the left-hand upper corner and segment expansion. This is actually, you can say we've pursued a three-pronged strategy, both geographic expansion across the lab sizes, as I talked about when explaining about the market, but also now not only being and offering a solution based on software and hardware, but also actually having charge of the reagents. We have the full system solution. Innovation-wise, that strategy is now reflected in our capabilities, so we can do innovation of a full system solution, hardware, software, applications, reagents, which means we actually control the entire workflow to provide and improve diagnostic certainty. We are intending to do this and focus our innovation agenda, both short-term, medium-term, but also long-term. On the lower hand corner, we have our examples of our nimble business model that I already explained on the previous slides. In terms of our supply chain and our go-to-market model with partnerships, it's about simplicity, it's about high quality, and because we are respectful of the way we play and the diagnostic industry we play in, and also the way we reach the entire hematology market with our partnerships. Overall, in the green buckets, you see our kind of ambitions of having 15% organic growth per year over an economic cycle. Also on the profitability, we take pride in having exceeding 20% profitability, which has certainly been the case if you look in the past. Next slide, please. You can press twice, because that leaves the concluding slide that summarizes my introduction to CellaVision, which is about the overview of the hematology workflow. On this slide, you will see how our business model and our offerings allows us to connect with complete blood counters or the companies offering the complete blood counters. Yes, this slide, please. Across the different lab sizes, as we've talked about today, also, what is very pivotal here is that not only can we address, we can say horizontally, the large labs and the small mid-size labs now, we can also bundle them together with connectivity. We can really serve the integrated hospital networks with our solutions for smaller labs, larger labs, can bundle them together with remote review software and other value-driving components. Essentially, CellaVision has taken a large share. We've aligned with our distribution partners, and we're delivering diagnostic certainty via this workflow with reliability, accuracy, and standardization. That's kind of the intro, and now I think we should jump into the financial results for 2021 Q1. I'm happy to just have a sip. I'm happy to present a result of ending at SEK 134 million for Q1. It's a result that reflects organic growth of 7%, but it also reflects a foreign exchange impact of negative 7%, which gives us pretty much a flat year-over-year comparison. If we dive into the different regions, starting with Americas, this is where we have seen a decreased minus 23% against last year, which was a tough baseline in the light that Q1 was pre-COVID. If we really go down to the chart on the right-hand side and look at the blue bar in the bottom for Americas. We can see that actually in the U.S., COVID kind of impacted Q2 significantly. It was a dip right away into Q2. Ever since then, we've had an upward trend ever since in 2020, and we are seeing that continuing. That's really the positive news that we are seeing traction. We still have high attachment rates. When our partners are placing their cell counters, then we are attached in those deals. We still see 9% attachment rate, which is really a healthy sign. I've talked about the DC-1 serving the small customers, and as I said, in the previous quarter, we got 510(k) for DC-1 in the U.S. It has a strong potential in the U.S. We have a strong pipeline for DC-1 when we correspond with our partners. The DC-1 really has a strong value proposition, which is tailored to the U.S. lab and hospital structure. It's about integrated hospital networks over there, and it's also about hospital consolidation. It really fits the value prop for the U.S. We're very, very excited about the opportunity to grow the business via DC-1 as well. We don't have a lot of sales of reagents, our RAL product line is in process and getting introduced. In brief, I'd say 2020 was about contract management, and here we are entering the phase of testing tryouts and demonstrating the stains with customers to drive adoption and to train our distributors. That's an exciting growth driver there. Going into APAC. Here, our sales decreased 6% down to SEK 24 million, still key markets being China and Japan. We saw some removal of old placements in Japan, which gave a good, healthy contribution to our quarter. Going into DC-1 for APAC, which is also an interesting product to serve that market. It does represent a new value proposition in APAC. APAC is more fragmented. It's not as obvious as compared to U.S. I just talked about. There are less integrated hospital networks, and we're learning about the price sensitivity versus quality parameters in APAC. This is a market where we have certainly started our adoption. I would say in Q1, we sold 50% of the total sales in 2020. We are on a good trajectory. There is certain interest, but it comes in various shapes and also the different countries. We see Australia, Korea, and India, especially on the COVID, which actually hinders our opportunity to go to the labs, demonstrate it, because that is where you will need a physical presence. That's the short version on APAC. Coming into EMEA, sales grew by 24% to an all-time high quarter of SEK 68 million. That's on top of a very good quarter in Q4. We're obviously very pleased with that. The main drivers here were France and Germany. Nordics and Benelux also had positive contributions here. When we analyze the markets, there were no sort of strictly speaking one-off per se. However, for Germany, we did see some sizable tender deliverables, tenders that had been won in early 2020. It's not only a long sales cycle, but it's also a long delivery cycles for our products. We saw some tailwind from Germany in this quarter, which also means that when we look forward and we discuss with our partners, there is optimism around France, but there is less optimism, a bit more insecurity as to what the market will bring for Germany. That goes also for the other markets. The fact of the COVID with the potential new lockdowns can actually hamper our sales activity. That's the biggest risk we see in Europe, different countries, different levels of vaccinations. That's where we are on that. I think there's one good thing I also want to emphasize on Europe. We had a strong quarter with RAL. In fact, we had 10% growth in Q1 year-over-year in local currency, in EUR, which then translates into 3% growth in SEK. However, another good quarter there. Okay, next slide, please. Here, taken together a few key themes. Here we've highlighted a section on COVID, because it has impacted us, and it is still impacting us and will do so in this year. Looking back, COVID came in Q1, and momentum was actually lost over the course of six months, except for U.S., where we kind of saw this steep drop. In this recovery phase where we are vaccinating, vaccination is a leading indicator as to when we see business activities coming up. We also expect that there will be a timing. It will take time for us to regain the activities, the access to the labs. However, we're doing everything we possibly can also to educate our partners and train them. Time is certainly not wasted, but airtime is something we're looking forward to. The DC-1, the strongest adoption for DC-1, it's in Europe. That's where we've seen really good traction. Also, in Q1 for Europe, we saw 50% sales of the total sales in 2020. Remember, we had CE mark for Europe the entire 2020. Adoption, it does have a traction. U.S., I said, strong potential for DC-1, and we've started. We see traction in APAC, but there are much more to learn about those segments in APAC to get them the structure. China, yes, tests and evaluations are ongoing. You can say briefly, we did a lot of documentation throughout last year, and this year is about the testing. It's also a partnership with the authorities out there. That's work ongoing in terms of type testing and clinical trial. I'll speak a bit about reagents in a sec, but finally here, I just want to say it's been a pleasure also to my team members. It's been a pleasure joining and being the CEO now for two months and really getting on the inside of CellaVision. It's a very strong company. Strong capabilities, strong culture across RAL and CellaVision. Two reasonable old. RAL also very old legacy. Combining those is really, I think it's a very winning model in diagnostics because we now have software, hardware, reagents, expertise to build our full system solutions and control them. My focus will certainly be on innovation and commercialization. We, on the innovation piece, I'll emphasize that we need to stay and remain relevant short term to medium term. We are really working. There's a strong roadmap here at CellaVision, and we are obviously refining and expanding on that. Then we want to lead long-term innovations to balance our roadmap. A good example of this, even though it's Q1 reporting, but just after closing Q1, we finalized our due diligence on the exclusive rights or the IP of the FPM, the Fourier ptychographic microscopy technology. That's a long-term investment that has given us the exclusive rights to this technology. It provides us or allows us to actually build high-resolution images or compose high-resolution images, but using low magnification optics. In other words, we can extract information from these photos with low magnification optics, the existing optics out there, if you like. We can do it with high speed. This really speaks to a diagnostic workflow, which is very interesting for the future. It's on feasibility testing now, and as we've said, this has potential. This is why we're excited about it, but we're still in a very early phase. We are doing feasibility testing, we're doing prototyping of it. This is an example of how we want to build on the foundation we have today. Furthermore, commercialization, I think we've done very well. The team has done very well in acquiring RAL. It's a great team, and the adoption of the products and bundling it together with our other solution is on the agenda for us to build these ultimate diagnostic solutions. The DC-1 adoption that ties together the networks and the value probably in both smaller labs and with the less samples is really key. We have very important agenda points or topics on our strategic agenda here. Let's go to the next slide. Here we have the development, and as you can see, the number was SEK 134 million for the quarter. Pretty much equivalent to Q1 last year. As already said, negative growth plus seven, minus seven with the FX impact. If we look at the gross margin, it's actually pretty strong at 69%. It's on par with Q1. We had improvements if we compare with Q2, Q3, Q4 last year. We had a better product mix with additional instruments. Also we had an increase in software, which is driving profitability upwards, and that was primarily in the U.S. Especially the remote reviews, which fits with the integrated hospital networks. This actually translate into the highest EBITDA of SEK 46.2 million. That's a great result. It actually also translated into a very strong operating cash flow of SEK 26 million, which is higher than the compare of SEK 15 million the year before. Furthermore, the total cash flow, when we go deeper down, it's SEK 8.8 million, up against minus SEK 5.2 million last year. On top of this, it's actually despite the fact that we decreased our [inaudible] by approximately SEK 6 million. It's a very strong quarter also on the cash flow side. The next slide. Here we display the development of our company for the past five years, and also having a rolling 12 months on the very right-hand side. We have been growing on average 15%, but obviously 2020 was a historical unprecedented year, has taken us somewhat down. What I really want to point out here to summarize is the business model. The example we see, especially when we look at the operating expenses on the chart down there, the light blue line, and we see our flexibility in our business model. COVID comes in early 2020, and we could instantaneously do tight cost control and be agile to actually level off our operating expenses, which meant that we could maintain good margins. We've had no layoffs. We're still ready to drive our agenda forward. We kept new hires on a lower level, but we are ready, which is really a good platform for the future. I think we're almost at the 30 minutes mark that was allocated here. I actually suggest we pause here or stop here, and then we enter the Q&A, and Magnus Blixt and myself will be happy to answer any questions you may have. Thank you. Ladies and gentlemen, if you do wish to ask a question, please press zero one on your telephone keypad now. That is zero one to register for a question. We have a question from the line of Ulrik Trattner from Carnegie. Please go ahead. Thank you very much. Hi, Simon and Magnus. I have a few, but I'll start off and just cut me off if there are too many of those. EMEA development, obviously very strong, highest sales recorded for you guys. As you mentioned, there were some tender deliveries in Germany. Could you help us decipher what else is driving growth in EMEA? Is there anything left on that tender to be delivered? Is there any further tender deliveries expected in the next few quarters? I'd say generally it is a tender-based business. We continuously have tenders that come and go. This tender that I explicitly just spelled out was a sizable tender. That is coming to an end. That was something that contributed for Q1, which will not continue. That's on the tender piece, Ulrik. I think what drives growth here is we still expect we have on the RAL side, on the reagent side, we have a strong footprint. We still, by then a stronger, higher base of our reagents on RAL. We see unhindered traction in Europe, which is where you asked about. This is also the growth driver, especially for APAC and Americas, where we hardly had any sales. On the DC-1, I said that's a growth driver for Europe, certainly. Highest adoption, as I said. Actually, we also expect that that will glue in because we also have some level of integrated hospital networks in Europe, and that will glue in also the demand for our larger DM platforms. Great. If we were just to move to Americas, and we have received quite positive comments from other med tech companies with high exposure to the Americas and capital equipment. Is there anything specific that's why your sales is down, especially for system sales to be down closely to 60% in the quarter? When do you expect it to be back to normalized levels? Perhaps, is there still some delays in terms of the sales cycles as you are reliable on distributors? As we could also then just keep our focus on the U.S. market, and you quite recently reintroduced the RAL product offering in the U.S. What has been the initial feedback on the reagents in the U.S.? The initial feedback, there we've really spent last year also having the contract management around our portfolio and having that discussion with our partners. Now it's about testing and tryouts of the reagents. It's for hematologists and immunologists, they want to see the stain themselves. That has been challenged. That's challenging in an environment where we've not been able to access the labs. That has hindered kind of progress on that. We've done internal work, but not that much external work specifically for them. If we go to the decline, I'd say if you look at the trajectory, it's a steady increase we see over the course of quarters. With vaccination of, well, 35%, 40% of the population having had the first shot, we think that also translate into access to labs. What we hear from our partners is that certain hospitals, it is actually possible to go, but we're not at the level where we used to be. There's still online meetings and so forth, and that format, the virtual meetings, are okay for an established business, or if we have, you can say, a sales call related to our larger instruments. It's harder with new innovations like the RAL portfolio for the U.S. or the DC-1. That's where you want to see it, you want to demonstrate it. That's what drives. We still think that throughout 2020, we expect also with the pipeline we hear from our partners, that we will have this gradual increase. Okay. Clear. Thank you. On to APAC. If we can start off, you mentioned the delays for DC-1 in launching into China. Can you please help us clarify when we are expected to have the DC-1 cleared and approved on the Chinese market? As well as looking at the entire APAC region, would you consider the situation being worse than it was one year ago? We are also seeing in Q1, I know it's hard to do quarter-on-quarter comparison for you guys, we're seeing a sequential decline in sales for APAC. Should that be more viewed as Q4 was especially strong, or has the situation become more problematic for you guys? I think if we start with the DC-1 going into China, the exercise we have to do there is very dependent on external, the authorities to do the type testing and also the clinical trials, which has to be conducted in China. That's the first thing. Is that after 2021, or are we coming into 2022? That's the question. On top of that, I would say specifically for China, there are not integrated hospital networks to the same extent as we see especially in Americas and partly in Europe. That's not the case in China. This is where we also got to learn, as we have the product and start testing, having the conversations with the customers out there, what is the market opportunity for the product in China? What segments, the Class II, Class I, can we actually address it, and is the pricing acceptable? That's something we are looking at if we're looking at China. Across the region, we've highlighted the countries where we really see impact from COVID getting access in places like India is obvious, Korea, Australia. We still get the inputs that it's a very compelling product with DC-1. We're very excited about it. Again, a new product being introduced in a market where you cannot demonstrate it's challenging. That calls for some, you can say, unclarity as to how and when we build momentum in those fragmented markets. Okay, great. Just going back to, you mentioned that there potentially could be sort of price discussions for DC-1 in China. Are you evaluating pricing the DC-1 lower into APAC in comparison to EMEA and Americas? That would deviate from your historical pricing of your portfolio, right? No, this is a conversation we will have also with our partners. Remember, the way we sell is in a total solution for the hematology lab. This is something we address essentially country by country with the partners. Okay, great. Two last questions on my end, please. Can we just talk about the production capacity for RAL? It's been more of a stable business, and we're seeing volume is picking up. Is there any bottlenecks in your current production capacity, which needs to be addressed in order to align with your ambition on the products of RAL growing in the next few years? Yeah, we are actually expanding our manufacturing footprint in France to cope with volume increase and also to standardize some processes. That's an ongoing project where we will see. We are expanding the factory as we speak. In the planning phase, and we'll see some investments coming in this year, with potentially a small spillover to 2022. It's a great question, Ulrik Trattner, you point towards a key strategic initiative, an enabler for us that we are focusing on to support the growth of RAL. Great. Thanks. Last question, just a quick one. Two-part question on the new FPM technology. It's just, will the full sort of SEK 29 million fee be paid in full during Q2, and is there any integration-related costs to buying this technology over the next few quarters? We will pay 90% of the amount in Q2, the remaining 10% will be in 2022. Great. Any integration-related costs, or it will just be integrated into next development projects? Yeah. I'm sorry, can you read? Integrated, you mean are there costs related on top of Yeah. Exactly. Yeah. Services. Yeah. We have some, I'd say, insignificant costs related to the transaction that we will carry in our P&L. Okay. That's great. Thank you very much, Simon Østergaard, for taking the question. I'll just go back to you, Pia. We have a question from the line of Carl-Oscar Bredengen from Berenberg. Please go ahead. Hi. Morning, everyone. You mentioned that you see that the activity level is starting to pick up. Can you talk a little bit about when throughout the quarter you started to be able to do physical meetings in several of the jurisdictions that you were successful in, and how you're seeing the pipeline sort of escalate? Has there been a lot of postponed projects in the pipeline that are now starting to pick up again? To which extent are you seeing that activity thread increasing going forward? If we go back to Europe, it's kind of weird. In the southern part, we can actually visit and see customers. In the northern part, also in Germany and France, we don't travel. We don't have access to labs. It's not totally correlated with our sales numbers, and that's back to the fact that the sales cycle is out of sync. When do we see the customer does not translate into a sales number in the same quarter. That's one dynamic. Europe is really fragmented. We've actually seen most activity in the south, believe it or not. We were kind of surprised when we learned this. U.S., it's gradually, it really follows the activity level, gradually being able to see the labs. That is coming on board. I think there is a bit of confidence over there as well, given the vaccinations. I think that kind of correlates with that. As we hear from our partners and from our market support organization, we are not at 100% yet. Could be at 50%, but we're on an upwards trajectory in terms of visits and face-to-face demonstrations. That's kind of the short version for Europe and the Americas. Okay. Thank you. A small positive development in the gross margin. Was anything particularly related to that, or is that just more a quarterly one-off? We had a good product mix, that contributed. We also, if you see one of the slides, we actually show the sales per product group. We had a significant increase in software, which translated into gross margin as well. Good gross margin. That was a key contributor for the improved GM. Dependent on the mix, we don't hope it's a one-off. Thank you. That is it for me now. I'll just get back into the queue. Thank you. Pleasure. I remind you that if you want to ask a question, please press zero one on your telephone keypad now. We have a question from the line of Felix Wienen from SFO. Please go ahead. Hi, Simon. Magnus. Great to meet you, Simon, for the first time. Welcome to the company. Likewise. Which we follow since four years now very closely, and obviously, Klas and Magnus have done an excellent job over that time. It's great to see you come in with fresh eyes and an ambition to take the company to the next level. Given that we meet here for the first time, maybe you can just start and reflect again on your career experience so far, in particular with regards to driving revenue growth and execution, and also related to an indirect business model like this one. That would be great. Yeah. Career-wise, the indirect business model is certainly not new to me. I've been managing a business with Agilent Technologies for four, five years back in the days, where we also were commercializing products in an indirect model with the majority of the IVD players. I think it allows for a very new setup with fast action. I saw the same benefits of the way and the good decisions that CellaVision has taken over time. That's a plus. I'd say from my experience in pathology, this is also a business, it's tissue-based diagnostics, but it resembles what we do here at CellaVision significantly. Here, it's the format or the sample is blood, whereas in tissue-based, it's obviously tissue. The nature of the business is very similar, placing instruments, having reagents, a consumption, and a recurrent business model. I think here at CellaVision, with the acquisition of RAL, we are getting the opportunity to contribute and add to our revenue stream with more recurrent characters. That's both software, but it's certainly also the potential with the related business. That's something I've been working extensively with. Here, we don't control the end customer in the setup of CellaVision. We are working with our distribution partners, which is different from our previous experience, where we primarily were selling directly into the labs. That's the job of our partners, which means that the business model for them is around also price per analysis or price per slide and so forth. That's a different setup for us as we are contributing to our partners. The last thing I want to highlight also career-wise is, I've always worked in the sphere of business development, innovation, and commercialization. It's kind of been across those areas. I see the innovation agenda here at CellaVision. It's a super healthy company. We can be very ambitious on behalf of innovation, to maintain our position but not be complacent. I think that's important. We don't want to become complacent. We want to be aggressive and be seen as the leader, and that's some of the activities we're working on, and I have a lot of respect for what has been done in the company. As I'm going to tell my folks here in the company later, it's not about building a turnaround, but there are things we really need to get our arms around, and we have all opportunities with the capabilities that are possessed in this company. It's going to be an very interesting journey ahead of us over the next many years. Excellent. That's great to hear, and you sound very motivated, so I'm very keen to follow that over the next couple of years. Thank you. Pleasure. Another question probably touches a bit the innovation point of view. One area of the story that excites me very much, but where we've unfortunately not seen a lot of progress over the last couple of years is the veterinary space. From what I look at in the market, we see a lot of consolidation in the U.S., in particular on the lab side. Now it's also starting in Europe. I think it's a fantastic market to launch your products, cut the costs for the labs, while also raising the standard and the outcome. Your views around that would be interesting. I think also CellaVision launched a product together with IDEXX Laboratories, and I would be keen. They have big plans for the hematology side there. I would be keen to hear about progress and customer feedback. Yeah, I think you're right. The vet is actually an interesting segment. What we've recently heard from our partners in the U.S. is that throughout COVID, the companion segment has grown. It has really expanded. It is an interesting segment. This is also about building contracts with the labs or a chain of labs. There at CellaVision, we've been kind of really had one larger relationship, but this is something that is a growth opportunity to look into because we actually have the offering. Certainly, that is an interesting segment. It's never going to grow as big as the human. It's not, but it's certainly not insignificant. Yeah. Perfect. Excellent. The last one, I quickly touched on it previously, is just again about service and software. Just curious about the visibility. Q1 seems to be a strong quarter, and it has been last year as well. Unfortunately, it tapered off during the following quarters. Any hint whether we should expect that to remain stable or accelerate, decelerate sequentially would be fantastic. Thank you. Yeah. We actually have reasonable confidence around Q2. Underneath the reasonable, I would say there is some concerns that we share with our partners on the uncertainties in Europe with the on-and-off lockdowns. That's one thing. However, we are not super concerned around Q2. Our mind is also because we are starting to see orders coming in, and it looks healthy. The question is also, can we maintain it for the full- year? That's a bit early for us to comment on that. Sure. Thank you very much for the color. My last question is about APAC again. I remember that I think in 2019, you won a bigger order, a tender in Australia that was up for delivery in 2020 and 2021. Just from a contextual point of view, do I remember that correctly? Does that mean that we should expect growth to clearly step up on the instrument side in APAC during the remainder of the year? Thank you. Yeah. To my best knowledge, Magnus may correct me here. There is no clarity on the particular tender you mentioned from 2019 yet in Australia. That's still pending. We would love to see that happen, honestly. We are not there yet. You mean in terms of continuing to deliver or starting to deliver? Starting to deliver. Okay. Thank you very much. Pleasure. As a final reminder, if you would like to ask a question, please press zero one on your telephone keypad now. There are no further questions registered, I hand back to the speakers for any closing remarks. Thank you very much. First of all, thanks for everybody for listening in and providing the meaningful questions. As said in the beginning, it's a pleasure to represent CellaVision here today. I'm looking forward to our many earnings call in the future. I think we have a great opportunity with the company, and I've been extremely excited coming into the company, meeting the team, being exposed to the culture, but also seeing that we can actually make a difference for hematology here. That's exciting. With that, I will close our Q1 interim report presentation, and I'm looking forward to our continued discussions in the future. Thanks.